1 / 17

Boceprevir Combined with Peginterferon alfa-2b

miracle
Download Presentation

Boceprevir Combined with Peginterferon alfa-2b

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Nave Patients with HCV Genotype 1 SPRINT-2 Final Results Mark S. Sulkowski, Fred Poordad, Jonathan McCone Jr, Bruce R. Bacon, Savino Bruno, Michael P. Manns, Ira M. Jacobson, K. Rajender Reddy, Navdeep Boparai,Vilma Sniukiene, Clifford A. Brass, Janice K. Albrecht, and Jean-Pierre Bronowicki For the SPRINT-2 Investigators

    2. Boceprevir (BOC) is a linear peptidomimetic ketoamide serine NS3 protease inhibitor

    3. Study Objectives

    5. SPRINT 2: Study Design

    6. Baseline Characteristics

    8. SPRINT 2: SVR and Relapse Rates (ITT) Non-Black and Black Patients

    9. SVR Based on Week 8 HCV RNA in Non-Black Patients

    10. SVR in patients with undetectable HCV RNA between Weeks 8-24

    11. Treatment discontinuations due to stopping rule at Week 24 in Non-Black patients

    12. SVR Results in Cohort 2 (Blacks)

    13. SVR and Viral Resistance According to the Week 4 Log10 Decline in HCV-RNA* in Non-Black Patients

    14. Most Common Treatment-Related Adverse Events*

    16. Conclusions

    17. Acknowledgements

    18. Frequency Distribution of Post-Baseline RAVs Data from HCV-SPRINT-2 and HCV-RESPOND-2

More Related